TY - JOUR T1 - Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to date JF - medRxiv DO - 10.1101/19009563 SP - 19009563 AU - Jolynne Mokaya AU - Anna L McNaughton AU - Phillip A Bester AU - Dominique Goedhals AU - Eleanor Barnes AU - Brian D Marsden AU - Philippa C Matthews Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/23/19009563.abstract N2 - Background Tenofovir (TFV) is a widely used antiviral treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well understood, and the topic remains contentious. We here present assimilated evidence for putative TFV RAMs with the aims of cataloguing and characterising mutations that have been reported, and starting to develop insights into the mechanisms of resistance and potential clinical significance.Methods We carried out a systematic literature search in PubMed to identify clinical, in vitro and in silico evidence of TFV resistance. The structure of HBV reverse transcriptase (RT) has not been solved; we therefore compared HBV RT to the crystal structure for HIV RT to map the likely sites of RAMs.Results We identified a ‘long-list’ of 37 putative TFV RAMs in HBV RT, occurring within and outside sites of enzyme activity, some of which can be mapped onto a homologous HIV RT structure. Based on quality and quantity of supporting data, we generated a ‘short-list’ of nine sites that are supported by the most robust evidence. Most resistance arises as a result of suites of multiple RAMs. Other factors including adherence, viral load, HBeAg status, HIV coinfection and NA dosage may also influence viraemic suppression.Conclusion There is emerging evidence for polymorphisms that may reduce susceptibility to TVF. A better understanding of HBV drug resistance is imperative to optimise approaches to public health elimination targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJM is funded by a Leverhulme Mandela Rhodes Scholarship. PCM is funded by the Wellcome Trust, grant number 110110. EB is funded by the Medical Research Council UK, the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData availability All data generated or analysed during this study are included in this published article (and its Supplementary Information files). https://figshare.com/s/7dcfa78cc5ed14094d6f 3TClamivudineADVAdefovirARTantiretroviral therapycccDNAcovalently closed circular DNACHBchronic hepatitis B virus infectionETVentecavir (ETV)HBsAgHepatitis B surface antigenHBVHepatitis b virusHIVhuman immunodeficiency virusLdTtelbivudineNANucleos(t)ide analogueRAMResistance Associated MutationRTreverse transcriptaseTAFtenofovir alafenamideTDFtenofovir disoproxil fumarateTFVtenofovir (the active component of both TAF and TDF)YMDDtyrosine methionine aspartate aspartate motif in HBV RT ER -